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Abstract: The amyloid beta peptide 42 (Ab42) is an aggre-
gation-prone peptide that plays a pivotal role in Alzheim-
er’s disease. We report that a subtle perturbation to the
peptide through a single chirality change at glutamate 22
leads to a pronounced delay in the b-sheet adoption of
the peptide. This was accompanied by an attenuated pro-
pensity of the peptide to form fibrils, which was correlat-
ed with changes at the level of the fibrillary architecture.
Strikingly, the incorporation of d-glutamate was found to
stabilize a soluble, ordered macromolecular assembly with
enhanced cytotoxicity to PC12 cells, highlighting the im-
portance of advanced prefibrillary Ab aggregates in neuro-
toxicity.
Alzheimer’s disease (AD) is a major neurodegenerative disorder
that affects over 35 million people worldwide.[1] Reflecting the
increase in life expectancy, these numbers continue to rise,
while no cure exists.[2] Amyloid b (Ab) is an aggregation-prone
peptide of 36–43 amino acids in length and has been strongly
implicated in the mechanism of AD.[3] The Ab42 peptide is
widely regarded as the most toxic Ab entity in AD, which has
been attributed to its high aggregation propensity.[4, 5] The ag-
gregation profile is complex, with diverse oligomeric, pre-fibril-
lary, and fibrillary states being formed. Over the past decade,
diffusible oligomers have been recognized as particularly neu-
rotoxic species.[4,5]
Familial AD can arise from diverse mutations within the
Ab42 sequence.[6] Over ten Ab42 mutations have been identi-
fied, most of which are disease-causing single amino acid alter-
ations. Strikingly, from those mutations, four AD-accelerating
variants are positioned on one specific amino acid—gluta-
mate 22 (E22)—which identifies the residue as particularly im-
portant in the context of Ab42 neurotoxicity. The four E22-
borne familial mutations have in common that they alter the
charge at that residue, either through amino-acid substitution
(E22G, Arctic, G=glycine; E22K, Italian, K= lysine; E22Q, Dutch,
Q=glutamine), or amino-acid deletion (E22D, Osaka).[6] Bio-
physical experiments demonstrated that those substitutions
enhance the Ab propensity towards oligomer,[7] or fibril forma-
tion.[8] To further examine the role of residue 22 of Ab42 on
structure and function of the peptide, we have created the
E22e chiral mutant 2 (e=d-glutamate). This subtle molecular
edit enables for an alteration of the sidechain disposition of
the peptide without affecting its physical properties, such as
size, charge distribution, and polarizability (Figure 1).
We studied the effect of the introduction of d-glutamate at
position 22 on the aggregation propensity of Ab42 by con-
ducting thioflavin T binding experiments (Figure 2A). Remarka-
bly, the chiral E22e mutant 2 exhibited a fivefold reduction in
the fibril-formation rate compared to the wildtype (WT) pep-
tide 1 (t1/2[E22e]=65.6 min; t1/2[WT]=13.4 min). The rate of the
fibril formation of 1 was comparable to those previously re-
ported in the literature.[9–11] The aggregation ability of the
Ab42 peptide is believed to stem from its propensity to under-
take a secondary structural transition from a random-coil-like
structure to a b-sheet configuration.[3] We therefore examined
the time-resolved circular dichroism spectra of the peptides
1 and 2 over a period of 24 h. In agreement with the thiofla-
vin T binding results, a delay in the random coil to b-sheet
configuration of the Ab E22e peptide 2 was observed (see
Supporting Information). These results demonstrate a reduced
Figure 1. The Ab sequence with glutamate 22 highlighted in blue. The differ-
ences between Ab40 and Ab42 are highlighted in red. Replacement of l-glu-
tamate with d-glutamate at position 22 enables for a subtle alteration of the
sidechain disposition.
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propensity of the peptide 2 for aggregation at the fibrillary
endpoint, as well as at prefibrillary stages.
The delayed aggregation kinetics of the E22e peptide 2 led
us to investigate whether the fibrillary assemblies of 2 were al-
tered compared to 1. To do this, both Ab42 WT 1 and Ab42
E22e 2 fibrils were grown for 7 days at 37 8C following proto-
cols by Tycko et al (see Supporting Information for details).[9]
Transmission electron microscopy (TEM) images of the wild-
type Ab42 fibrils (Figure 2B) showed a distinct fibrillary archi-
tecture, characterized by the presence of numerous branches
extending from the main fibril. This is of particular interest,
given recent reports suggesting that the Ab42-fibril formation
is a secondary nucleation-dependent process.[10] In contrast,
peptide 2 displayed more elongated, organized fibrillary struc-
tures devoid of branches (Figure 2C). Analogous TEM experi-
ments were conducted, following an incubation of the pep-
tides 1 and 2 for 2 h. The results were consistent in terms of
branching, which was observable for Ab42 WT, but not for the
E22e chiral variant (see Supporting Information for images and
further details).
The difference in the fibrillary morphologies between the
peptides 1 and 2 led us to further investigate whether altera-
tions in the prefibrillary structural assemblies could account for
the striking differences. Photochemically induced crosslinking
of unmodified proteins (PICUP) experiments were carried out
to gain insight into the distribution of the oligomeric states.[12]
Comparative analyses of the wildtype 1 and the E22e Ab42
peptide 2 were conducted at two time points, either immedi-
ately upon reconstitution or following an incubation for 24 h.
The oligomerization profiles of the two scaffolds 1 and 2
showed no statistically significant difference in the population
states of the oligomers (dimer–heptamer), indicating that any
differences in the fibrillary assembly of the two peptides oc-
curred at more advanced stages of the aggregation process
(Figure 3A,B, see Supporting Information for details). To inves-
tigate these late-stage prefibrillary structures we employed
small-angle X-ray scattering (SAXS) analysis. SAXS has been
shown to be a powerful technique for monitoring amyloid-re-
lated structural features.[13] We examined the SAXS curves of
both wildtype 1 and E22e Ab42 peptide 2 after initial reconsti-
tution and following 24 h incubation at 37 8C (Figure 3C,D).
For both time points, SAXS analysis of the peptide 2 demon-
strated a Bragg reflection corresponding to a species with a pe-
riodicity of 3.7 nm. This value is consistent with the dimensions
Figure 2. A) Aggregation kinetics of the Ab42 wildtype peptide 1 (black) and Ab42 E22e peptide 2 (grey) at 20 mm, monitored by the Thioflavin T (ThT) fluo-
rescence (lem=444 nm, lex=485 nm) at 37 8C. B,C) Representative transmission electron microscopy (TEM) images of the fibrillary architectures of the Ab42
wildtype peptide 1 (B) and the Ab42 E22e peptide 2 (C). The samples were incubated in phosphate buffer (20 mm, pH=7.4) at 222 mm before being diluted
to 200 nm for imaging.
Figure 3. All experiments were carried out in phosphate buffer (20 mm,
pH=7.4) A) Representative PICUP (photochemically induced crosslinking of
unmodified proteins) gels at both t=0 h and t=24 h. All PICUP experiments
were carried out in phosphate buffer at 50 mm, either directly after reconsti-
tution, or following incubation for 24 h. Corresponding experiments were
also performed at 20 mm (see the Supporting Information). B) Densitometric
analysis of oligomeric band intensity at t=0 h, (see Supporting Information
for t=24 h). C) Small-angle X-ray scattering (SAXS) measurements of the
Ab42 wildtype peptide 1 at t=0 h (black) and t=24 h (grey). D) SAXS meas-
urements of the Ab42 E22e peptide 2 at t=0 h (black) and t=24 h (grey).
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of a single unit of the wildtype Ab42 sequence found within
a fibril using NMR and in silico structural models.[14] No Bragg
reflection and an increase in the heterogeneity of the sample
was observed for peptide 1, reflected by the large variance at
high Q values.
The mechanism underlying the toxicity of Ab42 remains
a subject of active research. Diverse modes of cytotoxicity
have been proposed, including membrane disruption, induc-
tion of tau hyperphosphorylation, oxidative stress mediated
through copper complexation, brain insulin resistance/signal-
ing, and mitochondrial toxicity.[15] The original (fibril-centric)
amyloid-cascade hypothesis was reformulated when diffusible
Ab42 oligomers emerged as the more toxic species.[4c] To test
whether the prefibrillary stabilized structure of peptide 2 ex-
hibited an increase in cytotoxicity, we monitored the effects of
varying concentrations of the wildtype peptide 1 and the E22e
peptide 2 on rat pheochromocytoma PC12 cells (Figure 4). Ad-
dition of either peptide resulted in a reduction in the cellular
viability, determined by the cell proliferation reagent WST-1. At
20 mm, a 30% reduction in the cellular viability was observed
when dosing with the wildtype peptide 1 (Figure 4, WT). How-
ever, addition of the same concentration of the E22e peptide 2
resulted in an 80% reduction in the viability (Figure 4, E22e).
The cellular viability of the PC12 cells was also found to be
lower when peptide 2 was dosed at 10 mm, with a reduction in
the cellular viability close to 65%, compared with a 20% re-
duction when dosing with the same concentration of peptide
1 (for detailed graphical analysis see Supporting Information).
Preincubation (2 h or 4 h) of the peptides prior to administra-
tion did not affect their cytotoxicity (see Supporting Informa-
tion). Our E22e variant offers a unique way of trapping an ad-
vanced aggregation intermediate of Ab42 with enhanced tox-
icity, and highlights how a subtle structural change—a single
chiral substitution—can have profound effects on aggregation
and neurotoxicity.
In conclusion, incorporation of d-glutamate at position 22 of
Ab42 resulted in a peptide with attenuated propensity for mis-
folding and aggregation. Transmission electron microscopy
showed a striking difference in the fibril morphology. The E22e
peptide 2 exhibited elongated, ordered amyloid-beta fibrils.
This is in stark contrast to the Ab42 WT peptide 1, which dis-
played a fibrillary architecture, characterized by the presence
of a large number of sidechains protruding from the main
fibril. No difference in the population density of the oligomers
(dimer–heptamer) between the two peptides was observed.
However, SAXS analysis of the E22e peptide 2 showed the
presence of a unique Bragg reflection corresponding to a solu-
ble species with a periodicity of 3.7 nm. Cell culture studies es-
tablished a three- to fourfold increase in the cytotoxicity in re-
sponse to the E22e substitution in Ab42. This subtle molecular
edit therewith offers a tool to improve our understanding of
the Ab42 neurotoxicity.
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